lung cancer drug beats chemo for previously untreated patients
Send a link to a friend
[March 26, 2014]
Pfizer Inc's Xalkori delayed progression
of lung cancer longer than chemotherapy in patients who had never
previously been treated for the disease, according to results of a
late-stage study released on Tuesday.
The medicine, which received U.S. approval in 2011
for lung cancer patients who have a specific gene mutation, had
shown in a previous Phase III trial that it significantly delayed
disease progression among those who have already undergone
chemotherapy for non-small-cell lung cancer, the most common form of
Pfizer said favorable results from the latest trial, combined with
those from the earlier big study, establish that Xalkori is
appropriate for first-line as well as second-line use, meaning for
patients receiving initial treatment as well as for those who have
already undergone chemotherapy.
The drug is used among patients who have a mutation in the so-called
ALK gene, as determined by an approved diagnostic test. The mutation
only occurs in a small percentage of patients with lung cancer, but
makes them good candidates for treatment with Xalkori.
Xalkori, with current annual sales of about $350 million, is
expected to get a significant boost from the new data. Cowen and Co
has predicted the medicine will generate annual peak sales of $1.05
billion by 2020.
[to top of second column]
Pfizer is also developing an array of other cancer medicines that
work through new mechanisms, with the aim of becoming a major player
in the oncology field.
Pfizer shares were up 0.6 percent at $31.67 in midday trading on
the New York Stock Exchange.
(Reporting by Ransdell Pierson; editing by Lisa Von Ahn and Andrew
[© 2014 Thomson Reuters. All rights
Copyright 2014 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.